Neurochemical dementia diagnostics: State of the art and research perspectives

Proteomics

Volumn 8, Issue 6, 2008, Pages 1292-1301

  Lewczuk, Piotr ^a   Wiltfang, Jens ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Alzheimer's disease; Amyloid cerebrospinal fluid; Dementia; Tau

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; BLOOD CHEMISTRY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; HUMAN; NEUROCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; PHOSPHORYLATION; TAU PROTEINS;

EID: 41549142204     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700703     Document Type: Review

References (91)

1. Mayeux, R., Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol. Aging 1998, 19, 139-143.
2. Knopman, D., Pharmacotheraphy for Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 2001, 1, 428-434.
3. Bullock, R., New drugs for Alzheimer's disease and other dementias. Br. J. Psychiatry 2002, 180, 135-139.
4. Klafki, H. W., Staufenbiel, M., Kornhuber, J., Wiltfang, J., Therapeutic approaches to Alzheimer's disease. Brain 2006, 129, 2840-2855.
5. Reiber, H., Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 2001, 310, 173-186.
6. Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E. et al., Evaluation of CSF-tau and CSF-Ab42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 2001, 58, 373-379.
7. Blennow, K., Wallin, A., Hager, O., Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 1993, 88, 221-223.
8. The Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease, Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 1998, 19, 109-116.
9. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M. et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325, 733-736.
10. Panegyres, P. K., The amyloid precursor protein gene: A neuropeptide gene with diverse functions in the central nervous system. Neuropeptides 1997, 31, 523-535.
11. Klafki, H., Abramowski, D., Swoboda, R., Paganetti, P. A. et al., The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J. Biol. Chem. 1996, 271, 28655-28659.
12. Citron, M., Diehl, T. S., Gordon, G., Biere, A. L. et al., Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc. Natl. Acad. Sci. USA 1996, 93, 13170-13175.
13. Lichtenthaler, S. F., Beher, D., Grimm, H. S., Wang, R. et al., The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc. Natl. Acad. Sci. USA 2002, 99, 1365-1370.
14. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 1991, 82, 239-259.
15. Schenk, D., Barbour, R., Dunn, W., Gordon, G. et al., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400, 173-177.
16. Hock, C., Konietzko, U., Streffer, J. R., Tracy, J. et al., Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38, 547-554.
17. Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P. et al., Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat. Med. 2003, 9, 448-452.
18. Lewczuk, P., Esselmann, H., Otto, M., Maler, J. M. et al., Neurochemical diagnosis of Alzheimer's dementia by CSF Ab42, Ab42/Ab40 ratio and total tau. Neurobiol. Aging 2004, 25, 273-281.
19. Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A. et al., Highly conserved and disease-specific patterns of carboxyterminally truncated Ab peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 2002, 81, 481-496.
20. Blennow, K., Vanmechelen, E., Hampel, H., CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 2001, 24, 87-97.
21. Wiltfang, J., Esselmann, H., Maler, J. M., Bleich, S. et al., Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 2001, 47, 65-71.
22. Wiltfang, J., Lewczuk, P., Riederer, P., Grunblatt, E. et al., Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry 2005, 6, 69-84.
23. Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R. et al., Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38, 643-648.
24. Wiltfang, J., Esselmann, H., Smirnov, A., Bibl, M. et al., b-Amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann. Neurol. 2003, 54, 263-267.
25. Sjögren, M., Gisslen, M., Vanmechelen, E., Blennow, K., Low cerebrospinal fluid b-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 2001, 314, 33-36.
26. (1-42) and tau levels in CSF. Neurology 1999, 52, 1555-1562.
27. Galasko, D., Chang, L., Motter, R., Clark, C. M. et al., High cerebrospinal fluid tau and low amyloid b42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 1998, 55, 937-945.
28. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. et al., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33, 95-130.
29. Shahani, N., Brandt, R., Functions and malfunctions of the tau proteins. Cell Mol. Life Sci. 2002, 59, 1668-1680.
30. Mawal-Dewan, M., Henley, J., Van de Voorde, A., Trojanowski, J. Q. et al., The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. J. Biol. Chem. 1994, 269, 30981-30987.
31. Rosner, H., Rebhan, M., Vacun, G., Vanmechelen, E., Developmental expression of tau proteins in the chicken and rat brain: Rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. Int. J. Dev. Neurosci. 1995, 13, 607-617.
32. Sunderland, T., Linker, G., Mirza, N., Putnam, K. T. et al., Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289, 2094-2103.
33. Otto, M., Wiltfang, J., Tumani, H., Zerr, I. et al., Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 1997, 225, 210-212.
34. Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P. et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 2001, 297, 187-190.
35. Iqbal, K., Grundke-Iqbal, I., Zaidi, T., Merz, P. A. et al., Defective brain microtubule assembly in Alzheimer's disease. Lancet 1986, 2, 421-426.
36. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M. et al., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 1986, 83, 4913-4917.
37. Hu, Y. Y., He, S. S., Wang, X., Duan, Q. H. et al., Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : An ultra-sensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol. 2002, 160, 1269-1278.
38. Iqbal, K., Alonso Adel, C., El-Akkad, E., Gong, C. X. et al., Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci. 2002, 19, 95-99.
39. Lewczuk, P., Esselmann, H., Bibl, M., Beck, G. et al., Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in alzheimer's disease: Original data and review of the literature. J. Mol. Neurosci. 2004, 23, 115-122.
40. Vanmechelen, E., Van Kerschaver, E., Blennow, K., De Deyn, P. P., in: Iqbal, K., Sisodia, S. S., Winblad, B. (Eds.), Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, John Wiley and Sons Ltd., Chichester 2001, pp. 285-291.
41. Parnetti, L., Lanari, A., Amici, S., Gallai, V. et al., CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol. Sci. 2001, 22, 77-78.
42. Itoh, N., Arai, H., Urakami, K., Ishiguro, K. et al., Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 2001, 50, 150-156.
43. Hampel, H., Buerger, K., Kohnken, R., Teipel, S. J. et al., Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 2001, 49, 545-546.
44. Arai, H., Ishiguro, K., Ohno, H., Moriyama, M. et al., CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp. Neurol. 2000, 166, 201-203.
45. Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J. et al., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 2004, 61, 95-102.
46. Mulder, C., Scheltens, P., Visser, J. J., van Kamp, G. J. et al., Genetic and biochemical markers for Alzheimer's disease: Recent developments. Ann. Clin. Biochem. 2000, 37, 593-607.
47. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M. et al., Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90, 1977-1981.
48. Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B. et al., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278, 1349-1356.
49. Mayeux, R., Saunders, A. M., Shea, S., Mirra, S. et al., Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med. 1998, 338, 506-511.
50. Tumani, H., Nolker, G., Reiber, H., Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. Neurology 1995, 45, 1663-1670.
51. Reiber, H., Ungefehr, S., Jacobi, C., The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler. 1998, 4, 111-117.
52. Wiltfang, J., Esselmann, H., Cupers, P., Neumann, M. et al., Elevation of b-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J. Biol. Chem. 2001, 276, 42645-42657.
53. Ida, N., Hartmann, T., Pantel, J., Schröder, J. et al., Analysis of heterogeneous bA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 1996, 271, 22908-22914.
54. Wiltfang, J., Esselmann, H., Bibl, M., Hull, M. et al., Amyloid b peptide ratio 42/40 but not Ab42 correlates with phospho-Tau in patients with low- and high-CSF Ab40 load. J. Neurochem. 2007, 101, 1053-1059.
55. Lammich, S., Schobel, S., Zimmer, A. K., Lichtenthaler, S. F. et al., Expression of the Alzheimer protease BACE1 is suppressed via its 5′-untranslated region. EMBO Rep. 2004, 5, 620-625.
56. Kanai, M., Matsubara, E., Isoe, K., Urakami, K. et al., Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan. Ann. Neurol. 1998, 44, 17-26.
57. Schoonenboom, N. S., Pijnenburg, Y. A., Mulder, C., Rosso, S. M. et al., Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004, 62, 1580-1584.
58. Engelborghs, S., De Vreese, K., Van de Casteele, T., Vanderstichele, H. et al., Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 2007, in press.
59. Arai, H., Terajima, M., Miura, M., Higuchi, S. et al., Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. Ann. Neurol. 1995, 38, 649-652.
60. Golombowski, S., Muller-Spahn, F., Romig, H., Mendla, K. et al., Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci. Lett. 1997, 225, 213-215.
61. Blomberg, M., Jensen, M., Basun, H., Lannfelt, L. et al., Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow- up. Neurosci. Lett. 1996, 214, 163-166.
62. (1-42) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 2000, 284, 85-88.
63. Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M. et al., Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90, 8098-8102.
64. Andreasen, N., Minthon, L., Clarberg, A., Davidsson, P. et al., Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999, 53, 1488-1494.
65. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J. et al., Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 1999, 56, 303-308.
66. Andreasen, N., Vanmechelen, E., Vanderstichele, H., Davidsson, P. et al., Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol. Scand. Suppl. 2003, 179, 47-51.
67. Zetterberg, H., Wahlund, L. O., Blennow, K., Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci. Lett. 2003, 352, 67-69.
68. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E. et al., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006, 5, 228-234.
69. Lewczuk, P., Kornhuber, J., Vanderstichele, H., Vanmechelen, E. et al., Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiol. Aging 2007, in press.
70. Vignali, D. A., Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 2000, 243, 243-255.
71. Carson, R. T., Vignali, D. A., Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods 1999, 227, 41-52.
72. Olsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G. et al., Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 2005, 51, 336-345.
73. Vanderstichele, H., De Meyer, G., Andreasen, N., Kostanjevecki, V. et al., Amino-truncated b-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin. Chem. 2005, 51, 1650-1660.
74. Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P. et al., CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006, 129, 1177-1187.
75. Bibl, M., Mollenhauer, B., Wolf, S., Esselmann, H. et al., Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations. J. Neural. Transm. 2007, 114, 621-628.
76. Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H. et al., Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry 2007, in press.
77. Zerr, I., Bodemer, M., Gefeller, O., Otto, M. et al., Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 1998, 43, 32-40.
78. Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R. et al., Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid b peptides. Clin. Chem. 2006, 52, 332-334.
79. Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P. et al., Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000, 7, 245-258.
80. Lewczuk, P., Kornhuber, J., Wiltfang, J., The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics. J. Neural. Transm. 2006, 113, 1075-1080.
81. Lewczuk, P., Beck, G., Ganslandt, O., Esselmann, H. et al., International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 2006, 409, 1-4.
82. Felgenhauer, K., Beuche, W., Labordiagnostik Neurologischer Erkrankungen: Liquoranalytik und -Zytologie, Diagnose- und Processmarker, Thieme, Stuttgart 1999.
83. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C. et al., Peripheral anti-Ab antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001, 98, 8850-8855.
84. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M. et al., Brain to plasma amyloid-b efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295, 2264-2267.
85. Preston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A. et al., Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: Defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol. Appl. Neurobiol. 2003, 29, 106-117.
86. Di Luca, M., Pastorino, L., Bianchetti, A., Perez, J. et al., Differential level of platelet amyloid b precursor protein isoforms: An early marker for Alzheimer disease. Arch. Neurol. 1998, 55, 1195-1200.
87. Kuo, Y. M., Kokjohn, T. A., Watson, M. D., Woods, A. S. et al., Elevated Ab42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbPP metabolism. Am. J. Pathol. 2000, 156, 797-805.
88. Lewczuk, P., Esselmann, H., Bibl, M., Paul, S. et al., Electrophoretic separation of amyloid beta peptides in plasma. Electrophoresis 2004, 25, 3336-3343.
89. Graff-Radford, N. R., Crook, J. E., Lucas, J., Boeve, B. F. et al., Association of low plasma abeta42/abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2007, 64, 354-362.
90. van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J. et al., Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol. 2006, 5, 655-660.
91. Mayeux, R., Honig, L. S., Tang, M. X., Manly, J. et al., Plasma Ab40 and Ab42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology 2003, 61, 1185-1190.